USNA

USANA Health Sciences, Inc. (USNA) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended July 4, 2026, and the six months ended on that date. USANA operates as a global nutritional and wellness company organized into three reportable segments: Core Nutritional (direct sales), Hiya (direct-to-consumer children's health), and Rise (retail protein products). The company reported a net loss for the quarter, driven by declining sales in its core business and a significant goodwill impairment charge related to the Hiya segment.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Consolidated net sales decreased 5.3% year-over-year in Q2. Core Nutritional sales fell 4.0% (6.8% on a constant currency basis) due to an 8.1% decline in active customers. Hiya sales dropped 16.7% due to a challenging digital marketing environment. Rise sales grew 40.3% driven by new product launches.
• Goodwill Impairment: The company recorded a non-cash goodwill impairment charge of $29.1 million in the Hiya reporting unit. This was triggered by lower-than-expected financial performance and changes in near-term forecasts, including adjustments to market multiples and discount rates.
• Profitability: The company swung from a net profit of $9.7 million in Q2 2025 to a net loss of $21.4 million in Q2 2026. This was primarily due to the impairment charge, lower operating margins, and a higher effective tax rate.
• Customer Base: Total active customers in the Core Nutritional business declined to 384,000 (down 8.1% from 418,000 in the prior year). Hiya's active monthly subscribers decreased to 166,000 from 200,400.

Guidance, Outlook, and Risks

Management Commentary: Management stated that the goodwill impairment does not reflect a change in commitment to the Hiya business, which remains a strategic part of their long-term growth strategy. They noted continued challenges in attracting new customers in the Core Nutritional business and a difficult digital marketing environment for Hiya. Cost realignment initiatives implemented in late 2025 helped reduce SG&A expenses in the Core segment.

Liquidity: The company maintains a strong liquidity position with $168.6 million in cash and no outstanding debt on its $75 million credit facility. Operating cash flow for the first six months was $33.1 million.

Risks and Contingencies:

• Regulatory & Geopolitical: Risks include operating in China (BabyCare subsidiary), trade policies, tariffs, and geopolitical tensions (Russia/Ukraine, Middle East).
• Business Model: Dependence on the direct sales model and independent Brand Partners, which has seen a decline in active customers.
• Acquisition Integration: Risks associated with the growth strategies of acquired entities Hiya and Rise, including reliance on key retailers and digital marketing algorithms.
• Legal: Various lawsuits and claims exist in the ordinary course of business, though management does not believe they will have a material adverse effect.

Investor Verification Checklist

• Goodwill Impairment Details: Verify the specific assumptions used in the Hiya impairment analysis (discount rates, growth projections) to assess if the $29.1 million charge is a one-time event or indicative of deeper structural issues.
• Customer Churn Rates: Monitor the trend of active customer declines in the Core Nutritional segment, particularly in Greater China and Southeast Asia, to gauge the sustainability of the direct sales model.
• Hiya Subscriber Recovery: Assess whether Hiya can reverse the 17% decline in active monthly subscribers amidst rising digital marketing costs.
• Tax Rate Volatility: Review the effective tax rate calculation, which resulted in tax expense despite a pre-tax loss, driven by jurisdictional mix and the impairment charge.
• Debt Covenant Compliance: Confirm continued compliance with the credit facility covenants, specifically the EBITDA requirements, given the recent operating losses.